查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1993176

Butorphanol市場：按給藥途徑、分銷管道、應用和最終用戶分類的全球市場預測，2026-2032年

Butorphanol Market by Route Of Administration, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，Butorphanol市值將達到 2.9611 億美元，到 2026 年將成長至 3.1157 億美元，到 2032 年將達到 4.0017 億美元，複合年成長率為 4.39%。

主要市場統計數據
基準年 2025 2.9611億美元
預計年份：2026年 3.1157億美元
預測年份：2032年 4.017億美元
複合年成長率 (%) 4.39%

Butorphanol的藥理作用和製劑考慮的簡明臨床框架：闡明其在現代鎮痛策略中的地位。

Butorphanol在鎮痛治療中佔有獨特的地位，它既是鴉片受體促效劑又是拮抗劑，常用於臨床治療急性中重度疼痛。其動態特性結合了κ鴉片受體激動作用和部分μ鴉片受體拮抗作用，與完全μ受體促效劑相比，在療效和安全性之間實現了獨特的平衡。臨床醫師在權衡鎮痛效果與呼吸抑制及其他μ鴉片受體介導的副作用時，尤其在分娩和手術全期護理等情況下，會特別重視這些特性。

監管重點、供應鏈現代化和以病人為中心的照護模式如何融合，從而重新定義止痛藥的臨床和商業性方法？

包括Butorphanol在內的止痛藥領域正經歷變革，這主要得益於監管力度加大、以病人為中心的照護模式以及供應鏈現代化。隨著人們對鴉片類藥物合理使用和替代性疼痛管理途徑的關注度不斷提高，多方面治療方法正在加速，包括對某些適應症中具有混合促效劑-拮抗劑特性的藥物進行重新評估。同時，臨床上對非口服給藥方式的需求日益成長，促使臨床醫生和採購團隊重新考慮在其製劑中加入注射劑和鼻內給藥方案，從而在住院和門診環境中實現快速、劑量可控的鎮痛。

評估到 2025 年的最新關稅調整如何重塑整個鎮痛藥價值鏈的籌資策略、供應彈性工作和採購決策。

美國在2025年前實施和調整關稅，對與Butorphanol相關的醫藥價值鏈施加了多方面的壓力。關稅導致進口原料藥和特殊輔料成本增加，加劇了採購的複雜性，並可能促使生產商重新考慮其籌資策略。為此，一些生產商正在尋求供應商多元化、透過合約進行風險對沖，並與國內契約製造組織（CMO）合作，以降低進口關稅和物流中斷的風險。

以細分市場為重點的臨床和商業性見解，整合給藥途徑、治療應用、最終用戶需求和分銷管道，以提供可操作的知識。

細分市場分析揭示了Butorphanol在臨床應用、採購管道和患者獲取方面的顯著模式。根據給藥途徑，相關人員對注射劑、鼻腔劑和口服劑型進行比較和評估。注射劑途徑進一步細分為肌肉注射和靜脈注射，每種途徑都適用於特定的臨床工作流程，例如術前術後或急診醫療環境中的快速劑量調整。就適應症而言，布托啡諾在慢性疼痛管理、分娩疼痛和手術疼痛方面的治療定位各不相同，需要製定個人化的臨床通訊協定並對醫生進行培訓，以確保最佳的治療效果。

美洲、歐洲、中東、非洲和亞太地區的區域趨勢影響著鎮痛治療的監管管道、臨床引入和供應鏈設計。

區域趨勢正顯著影響Butorphanol的法規結構、臨床實務模式和供應鏈結構。在美洲，關於鴉片類藥物管理的政策討論以及健全的醫院急性護理網路正在推動布托啡諾在手術全期和分娩過程中的廣泛應用。同時，籌資策略日益重視供應的連續性和對不斷變化的監管要求的遵守。該地區的生產商和經銷商正在協調宣傳活動和配方支持，以體現這些機構的優先事項和嚴格的法律規範。

製造商、專業製藥公司和合約合作夥伴之間的競爭定位和策略聯盟的主題決定了供應可靠性和臨床滲透率。

製藥公司、專業製藥公司和合約研發生產機構 (CDMO) 之間的競爭與合作動態在Butorphanol的研發、生產和分銷中發揮核心作用。大型非專利生產商利用規模經濟和一體化供應鏈來支援穩定的生產和廣泛的分銷。另一方面，專業製藥公司則專注於製劑創新、特定適應症和醫療專業人員培訓，以實現產品差異化。契約製造和 CDMO 透過助力產能擴張、確保符合不斷發展的藥品生產品質管理規範 (GMP) 以及快速轉移本地生產所需的技術，發揮日益重要的戰略作用。

產業領導者可以實施的切實可行的策略措施，以加強鎮痛產品的供應韌性、臨床引入和分銷管道協調。

在瞬息萬變的止痛藥市場中，產業領導者可以採取多項切實可行的措施來提升臨床應用率、供應鏈韌性和商業性績效。首先，他們應優先進行有針對性的臨床教育，並與醫療機構的相關人員進行溝通，重點強調混合促效劑-拮抗劑製劑的臨床優勢及其在多方面疼痛管理通訊協定中的作用。其次，他們應加快供應商多元化，並考慮將關鍵生產流程外包至近岸地區，以降低進口關稅和物流衝擊帶來的風險，同時投資於合規和品管體系，以確保符合監管要求。

透明且符合倫理的調查方法，結合專家訪談、監管審查和三角資料檢驗，檢驗臨床和供應鏈見解。

本研究整合了來自一手和二手調查的訊息，包括對臨床專家、採購負責人和生產主管的結構化訪談，檢驗實際情況與臨床細微差別之間的微妙之處。二手調查納入了監管文件、同行評審的臨床文獻、藥物安全監測報告和公共公告，以闡明臨床模式和政策影響的背景。數據三角驗證確保了從專家討論中獲得的定性見解與已記錄的監管更新、臨床指南和可觀察到的供應鏈趨勢相一致。

明確的整合強調臨床定位、供應彈性和實證策略共同決定鎮痛方案在醫療保健服務中的未來角色。

總之，Butorphanol仍是一種重要的臨床止痛藥物，其效用取決於其藥理特性、給藥途徑以及疼痛管理決策的背景。監管力度加大、臨床範式向多方面鎮痛的轉變以及到2025年貿易政策的變化，都凸顯了適應性採購、有針對性的臨床合作和嚴格的安全監測的必要性。將這些要求納入採購、製劑策略和臨床醫生參與的相關人員，將更有利於維持藥物的可及性並展現其治療價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章Butorphanol市場：依給藥途徑分類

  • 注射
    • 肌肉內注射
    • 靜脈注射
  • 鼻噴霧
  • 藥片

第9章Butorphanol市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第10章Butorphanol市場：依應用

  • 慢性疼痛管理
  • 分娩疼痛管理
  • 手術期間的疼痛管理

第11章Butorphanol市場：依最終用戶分類

  • 門診部
  • 家庭醫療保健
  • 醫院

第12章Butorphanol市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章Butorphanol市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章Butorphanol市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國Butorphanol市場

第16章：中國的Butorphanol市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Animedica
  • Apotex Inc.
  • Apothecon Pharmaceuticals
  • Athanas Enterprise Private Limited
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Dechra Pharmaceuticals
  • Faunapharma
  • Fresenius Kabi AG
  • Hikal Limited
  • Hikma Pharmaceuticals PLC
  • Merck KGaA
  • Mylan NV
  • Novex Pharma
  • Pfizer Inc.
  • Richter Pharma AG
  • Sagent Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Sanochemia Pharmazeutika
  • Selectavet
  • Taj Pharmaceuticals Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Troy Laboratories NZ
  • Zoetis Inc.
Product Code: MRR-1A1A064C0322

The Butorphanol Market was valued at USD 296.11 million in 2025 and is projected to grow to USD 311.57 million in 2026, with a CAGR of 4.39%, reaching USD 400.17 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 296.11 million
Estimated Year [2026] USD 311.57 million
Forecast Year [2032] USD 400.17 million
CAGR (%) 4.39%

A concise clinical framing of butorphanol's pharmacological role and prescribing considerations that illuminate its place in contemporary analgesic strategies

Butorphanol occupies a distinct niche within analgesic pharmacotherapy as a mixed opioid agonist-antagonist that is frequently employed for acute moderate to severe pain management in clinical settings. Its pharmacodynamic profile, which combines kappa-opioid receptor agonism with partial mu-opioid receptor antagonism, gives it unique efficacy and safety trade-offs compared with full mu agonists. Clinicians value these characteristics when balancing analgesia against respiratory depression and other mu-mediated adverse effects, particularly in settings such as labor and perioperative care.

Clinical practice and formulary committees evaluate butorphanol through multiple lenses: route of administration flexibility, rapid onset in injectable forms, the convenience of intranasal delivery in outpatient and ambulatory contexts, and tolerability in diverse patient populations. Regulatory pathways and hospital protocols influence how healthcare providers integrate butorphanol into multimodal analgesia strategies, while pharmacovigilance continues to refine risk mitigation for opioid-related events. Amid evolving pain management paradigms and heightened scrutiny of opioid prescribing, butorphanol's pharmacological attributes sustain its role in targeted therapeutic scenarios.

How regulatory focus, supply chain modernization, and patient-centric care models are converging to redefine clinical and commercial approaches to analgesics

The landscape for analgesics, including butorphanol, is undergoing transformative shifts driven by regulatory scrutiny, patient-centric care models, and supply chain modernization. Increasing emphasis on opioid stewardship and alternative pain pathways has accelerated adoption of multimodal regimens where agents with mixed agonist-antagonist profiles are reconsidered for specific indications. Concurrently, clinical demand for non-oral delivery has grown, prompting clinicians and procurement teams to reassess formulary placement for injectable and intranasal therapies that permit rapid, titratable analgesia in both inpatient and outpatient settings.

Supply chain dynamics are also changing; manufacturers and healthcare systems are investing in redundancy, nearshoring of critical intermediates, and tighter quality controls to safeguard continuity. These shifts are complemented by digital health innovations that enable remote patient monitoring and telehealth-facilitated prescribing, which influence the roles of ambulatory care centers, home healthcare providers, and hospital systems in delivering analgesic therapy. Taken together, these forces are reshaping how butorphanol is positioned clinically and commercially, creating opportunities for differentiated formulations and targeted educational outreach to prescribers.

Assessment of how recent tariff policy adjustments through 2025 have reshaped sourcing strategies, supply resilience efforts, and procurement decision-making across the analgesic value chain

The imposition and recalibration of tariffs in the United States through 2025 have exerted multi-dimensional pressure on the pharmaceutical value chain relevant to butorphanol. Tariff-driven increases in the cost of imported active pharmaceutical ingredients and specialty excipients can amplify procurement complexity and incentivize manufacturers to reassess sourcing strategies. In response, some producers have pursued supplier diversification, contractual hedging, and partnerships with domestic contract manufacturing organizations to lessen vulnerability to import levies and logistical disruption.

These adjustments have downstream implications for formulary committees and healthcare purchasers who must reconcile pricing dynamics with commitments to uninterrupted clinical supply. At the same time, tariff changes intersect with regulatory and quality assurance priorities; organizations that accelerate localization of critical manufacturing steps often face initial capital and compliance investments that lengthen lead times but strengthen long-term resilience. As a result, strategic players emphasize supply transparency, batch-level traceability, and collaborative forecasting to mitigate the operational impacts of tariff policy shifts while maintaining stewardship of therapeutic availability.

Segment-focused clinical and commercial implications that align administration routes, therapeutic applications, end-user needs, and distribution channels into actionable insights

Insight into segmentation reveals meaningful patterns in clinical use, procurement pathways, and patient access for butorphanol. Based on route of administration, stakeholders evaluate injectable options versus intranasal delivery and oral formulations; the injection pathway is further differentiated by intramuscular and intravenous modalities, each aligned to specific clinical workflows such as rapid titration in perioperative or emergency settings. Based on application, therapeutic positioning varies across chronic pain management, labor pain, and surgical pain, prompting tailored clinical protocols and education for prescribers to ensure optimal outcomes.

Based on end user, adoption and utilization differ among ambulatory care centers, home healthcare services, and hospitals, with each setting presenting distinct procurement cycles, storage requirements, and administration competencies. Based on distribution channel, supply continuity is managed through hospital pharmacies, online pharmacies, and retail pharmacies, which collectively shape patient access and the logistics of replenishment. Integrating these segmentation lenses helps stakeholders align development priorities, clinical education, and commercial outreach to the settings and administration routes where butorphanol demonstrates the strongest clinical fit.

Regional dynamics shaping regulatory pathways, clinical adoption, and supply chain design across the Americas, EMEA, and Asia-Pacific for analgesic therapies

Regional dynamics exert a pronounced influence on regulatory frameworks, clinical practice patterns, and supply chain architecture for butorphanol. In the Americas, policy debates around opioid stewardship and robust hospital-based acute care networks drive concentrated use in perioperative and labor contexts, while procurement strategies increasingly emphasize supply continuity and compliance with evolving controlled-substance regulations. Manufacturers and distributors in this region calibrate educational outreach and formulary support to reflect these institutional priorities and rigorous regulatory oversight.

Across Europe, the Middle East, and Africa, heterogeneous regulatory environments and diverse healthcare infrastructures create differentiated adoption pathways; some jurisdictions prioritize community-based pain management and outpatient access, whereas others rely heavily on centralized hospital procurement and strict narcotics controls. These variations necessitate nuanced regulatory submissions and localized pharmacovigilance frameworks. In the Asia-Pacific region, rapid expansion of ambulatory care, growing home healthcare delivery models, and investments in localized manufacturing capacity shape demand dynamics, with regional players increasingly focused on scalability, cost-efficiency, and alignment with public health guidelines. Collectively, these regional currents inform market entry strategies, distribution partnerships, and clinical engagement models.

Competitive positioning and strategic collaboration themes among manufacturers, specialty firms, and contract partners that determine supply reliability and clinical uptake

Competitive and collaborative forces among manufacturers, specialty pharmaceutical firms, and contract development and manufacturing organizations are central to how butorphanol is developed, produced, and distributed. Large generic manufacturers leverage scale and integrated supply chains to support steady production and broad distribution, whereas specialty companies focus on formulation innovation, niche indications, and provider education to differentiate products. Contract manufacturers and CDMOs play an increasingly strategic role by enabling capacity expansion, compliance with evolving good manufacturing practices, and rapid technology transfer for localized production.

Strategic collaborations between commercial teams and clinical educators drive adoption in targeted settings, while supply chain partnerships emphasize redundancy and regulatory alignment. Companies are also investing in pharmacovigilance infrastructure, real-world evidence generation, and lifecycle management to sustain product relevance amid heightened scrutiny of opioid therapies. Taken together, these dynamics highlight the importance of operational excellence, clinical engagement, and adaptive commercial models for stakeholders involved in the butorphanol value chain.

Practical strategic measures that industry leaders can implement to fortify supply resilience, clinical adoption, and channel alignment for analgesic products

Industry leaders can take several practical, actionable steps to strengthen clinical adoption, supply resilience, and commercial performance in the evolving analgesic environment. First, prioritize targeted clinical education and institution-level stakeholder engagement that highlights where mixed agonist-antagonist agents can offer clinical advantages and how they fit within multimodal pain protocols. Second, accelerate supplier diversification and consider nearshoring key manufacturing steps to reduce exposure to import tariffs and logistics shocks while investing in compliance and quality systems to maintain regulatory alignment.

Third, tailor distribution strategies to the operational realities of ambulatory care centers, home healthcare providers, and hospitals by optimizing channel partnerships with hospital pharmacies, online dispensaries, and retail outlets to preserve access. Fourth, invest in pharmacovigilance and real-world evidence programs that substantiate safety and efficacy profiles in the settings most relevant to product use, thereby facilitating informed formulary decisions. Finally, leverage collaborative contracting and shared-risk procurement models with healthcare systems to build long-term partnerships focused on continuity of supply, cost predictability, and clinical outcomes.

A transparent and ethically grounded research methodology combining expert interviews, regulatory review, and data triangulation to validate clinical and supply insights

This research synthesizes primary and secondary information streams, including structured interviews with clinical experts, procurement officers, and manufacturing executives to validate operational realities and clinical nuances. Secondary research incorporated regulatory filings, peer-reviewed clinical literature, pharmacovigilance reports, and public policy announcements to contextualize practice patterns and policy impacts. Data triangulation ensured that qualitative insights from expert discussions were cross-checked against documented regulatory updates, clinical guidance, and observable supply chain developments.

Methodological rigor was maintained through transparent inclusion criteria for expert selection, standardized interview guides, and a replicable approach to synthesizing disparate evidence. Limitations are acknowledged where public data is sparse or where practice variability across jurisdictions limits generalizability; consequently, recommendations emphasize strategic flexibility and the need for localized validation. Ethical standards governed interactions with clinical informants, and proprietary data sources were treated under non-disclosure protocols to protect commercial sensitivity while preserving analytical integrity.

A conclusive synthesis emphasizing how clinical positioning, supply resilience, and evidence strategies together determine the future role of analgesic options in care delivery

In conclusion, butorphanol remains a clinically relevant analgesic option whose utility is shaped by its pharmacological profile, administration routes, and the settings in which pain management decisions are made. The confluence of regulatory scrutiny, shifting clinical paradigms toward multimodal analgesia, and changes in trade policy through 2025 underscores the need for adaptive sourcing, targeted clinical engagement, and rigorous safety monitoring. Stakeholders that integrate these imperatives into procurement, formulation strategy, and clinician outreach will be better positioned to sustain access and demonstrate therapeutic value.

Looking forward, success will favor organizations that combine operational resilience with nuanced clinical messaging and evidence generation. Emphasis on partnership models with healthcare systems, investments in localized manufacturing capabilities where feasible, and proactive pharmacovigilance will help balance stewardship objectives with patient access. Ultimately, a measured, evidence-based approach to product positioning and supply strategy will maximize the ability to meet clinical needs while navigating an increasingly complex regulatory and commercial landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Butorphanol Market, by Route Of Administration

  • 8.1. Injection
    • 8.1.1. Intramuscular Injection
    • 8.1.2. Intravenous Injection
  • 8.2. Nasal Spray
  • 8.3. Tablet

9. Butorphanol Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
  • 9.3. Retail Pharmacy

10. Butorphanol Market, by Application

  • 10.1. Chronic Pain Management
  • 10.2. Labor Pain Management
  • 10.3. Surgical Pain Management

11. Butorphanol Market, by End User

  • 11.1. Ambulatory Care Center
  • 11.2. Home Healthcare
  • 11.3. Hospital

12. Butorphanol Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Butorphanol Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Butorphanol Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Butorphanol Market

16. China Butorphanol Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Animedica
  • 17.6. Animedica
  • 17.7. Apotex Inc.
  • 17.8. Apothecon Pharmaceuticals
  • 17.9. Apothecon Pharmaceuticals
  • 17.10. Athanas Enterprise Private Limited
  • 17.11. B. Braun Melsungen AG
  • 17.12. Baxter International Inc.
  • 17.13. Boehringer Ingelheim
  • 17.14. Boehringer Ingelheim
  • 17.15. Bristol Myers Squibb
  • 17.16. Bristol Myers Squibb
  • 17.17. Dechra Pharmaceuticals
  • 17.18. Dechra Pharmaceuticals
  • 17.19. Faunapharma
  • 17.20. Faunapharma
  • 17.21. Fresenius Kabi AG
  • 17.22. Hikal Limited
  • 17.23. Hikal Limited
  • 17.24. Hikma Pharmaceuticals PLC
  • 17.25. Merck KGaA
  • 17.26. Merck KGaA
  • 17.27. Mylan N.V.
  • 17.28. Novex Pharma
  • 17.29. Novex Pharma
  • 17.30. Pfizer Inc.
  • 17.31. Richter Pharma AG
  • 17.32. Richter Pharma AG
  • 17.33. Sagent Pharmaceuticals, Inc.
  • 17.34. Sandoz International GmbH
  • 17.35. Sanochemia Pharmazeutika
  • 17.36. Sanochemia Pharmazeutika
  • 17.37. Selectavet
  • 17.38. Selectavet
  • 17.39. Taj Pharmaceuticals Ltd.
  • 17.40. Taj Pharmaceuticals Ltd.
  • 17.41. Teva Pharmaceutical Industries Ltd.
  • 17.42. Troy Laboratories NZ
  • 17.43. Troy Laboratories NZ
  • 17.44. Zoetis Inc.
  • 17.45. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BUTORPHANOL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BUTORPHANOL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BUTORPHANOL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BUTORPHANOL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BUTORPHANOL MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BUTORPHANOL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BUTORPHANOL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BUTORPHANOL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BUTORPHANOL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BUTORPHANOL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BUTORPHANOL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAMUSCULAR INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAVENOUS INJECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAVENOUS INJECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BUTORPHANOL MARKET SIZE, BY INTRAVENOUS INJECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BUTORPHANOL MARKET SIZE, BY NASAL SPRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BUTORPHANOL MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BUTORPHANOL MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BUTORPHANOL MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BUTORPHANOL MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BUTORPHANOL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BUTORPHANOL MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BUTORPHANOL MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BUTORPHANOL MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BUTORPHANOL MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BUTORPHANOL MARKET SIZE, BY CHRONIC PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BUTORPHANOL MARKET SIZE, BY LABOR PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BUTORPHANOL MARKET SIZE, BY SURGICAL PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BUTORPHANOL MARKET SIZE, BY SURGICAL PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BUTORPHANOL MARKET SIZE, BY SURGICAL PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY CARE CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BUTORPHANOL MARKET SIZE, BY AMBULATORY CARE CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BUTORPHANOL MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BUTORPHANOL MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BUTORPHANOL MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BUTORPHANOL MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BUTORPHANOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS BUTORPHANOL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL BUTORPHANOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. GCC BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 108. GCC BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. GCC BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. GCC BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. G7 BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 126. G7 BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. G7 BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. G7 BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. NATO BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 132. NATO BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. NATO BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. NATO BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL BUTORPHANOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES BUTORPHANOL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA BUTORPHANOL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA BUTORPHANOL MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA BUTORPHANOL MARKET SIZE, BY INJECTION, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA BUTORPHANOL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA BUTORPHANOL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA BUTORPHANOL MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)